ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
Related topics
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference

September 1, 2022 GMT

BOSTON--(BUSINESS WIRE)--Sep 1, 2022--

Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference on Thursday, September 8, 2022 at 8:00 a.m. ET at the Encore Boston Harbor in Everett, MA.

A live webcast of Ironwood’s fireside chat will be accessible through the Investors section of the company’s website at www.ironwoodpharma.com. To access the webcast, please log on to the Ironwood website approximately 15 minutes prior to the start time to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Ironwood’s website for 14 days following the conference.

About Ironwood Pharmaceuticals
Ironwood Pharmaceuticals (Nasdaq: IRWD), an S&P SmallCap 600® company, is a leading gastrointestinal (GI) healthcare company on a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. We are pioneers in the development of LINZESS® (linaclotide), the U.S. branded prescription market leader for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Under the guidance of our seasoned industry leaders, we continue to build upon our history of GI innovation and challenge what has been done before to shape what the future holds. We keep patients at the heart of our R&D and commercialization efforts to reduce the burden of GI diseases and address significant unmet needs.

ADVERTISEMENT

Founded in 1998, Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts.

We routinely post information that may be important to investors on our website at www.ironwoodpharma.com. In addition, follow us on Twitter and on LinkedIn.

View source version on businesswire.com:https://www.businesswire.com/news/home/20220901005002/en/

CONTACT: Investors:Greg Martini, 617-374-5230

gmartini@ironwoodpharma.comMatt Roache, 617-621-8395

mroache@ironwoodpharma.com

KEYWORD: MASSACHUSETTS UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Ironwood Pharmaceuticals, Inc.

Copyright Business Wire 2022.

PUB: 09/01/2022 04:01 PM/DISC: 09/01/2022 04:02 PM

http://www.businesswire.com/news/home/20220901005002/en